LCOCABASTINE is an extremely potent and highly selective HI-receptor antagonist which has been specifically developed as eye drops and nasal spray for the treatment of allergic rhinoconjunctivitis. Clinical (Fig. 2) . Therapeutic efficacy was generally found to be comparable in the two treatment groups, with no statistically significant intergroup differences reported during the course of the trial. In all, 61% of levocabastinetreated patients rated global therapeutic efficacy to be excellent or good compared with 62% on cetirizine.
Levocabastine and azelastine: The comparative efficacy of levocabastine nasal spray (0.5 mg/ml, two puffs per nostril twice daily) and topical azelastine ( '44 In order to assess whether combination therapy with an intranasal steroid could provide additional clinical benefit to that seen with a topical antihistamine alone, the efficacy of beclomethasone diproprionate nasal spray was evaluated as add-on therapy in a double-blind trial in 44 patients with allergic rhinitis who were already receiving intranasal levocabastine. 45 As might be expected, the severity of nasal congestion was found to be significantly lower in patients receiving both agents (p < 0.001), however, combination therapy was not associated with any additional improvement in the severity of other symptoms of allergic rhinitis compared with that seen with levocabastine alone (Fig. 4) . Levocabastine 45 Sodium cromoglycate is often considered as a primary treatment option for the treatment of allergic rhinoconjunctivitis in children due to its excellent adverse-effect profile. Results from paediatric trials suggest that levocabastine may be a more appropriate first-line therapy in this patient population being significantly more effective and as well tolerated. 5'5 A proposed algorithm for the treatment of allergic rhinoconjunctivitis is shown in Fig. 6 . It is apparent that the availability of an effective and well-tolerated topical antihistamine, such as levocabastine, is an important advance which broadens the range of therapeutic approaches available for the clinical management of allergic rhinoconjunctivitis. Clinical evidence available to date suggests that levocabastine is an attractive alternative to oral antihistamines and that this topical antihistamine should be considered as a first-line therapeutic option for the treatment of this atopic condition.
